Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2586972 | 0.92 | RORC (0.36) | MMP8MEN1KMT2ATRPV1RORC | |
| SCHEMBL3862542 | 0.77 | MMP8 (0.42) | MMP8PSMB5RORCMMP2MMP9 | |
| SCHEMBL7453712 | 0.70 | TP53 (0.38) | TP53MEN1KMT2AL3MBTL1MMP2 | |
| SCHEMBL5981554 | 0.64 | MCL1 (0.39) | TP53MEN1KMT2A | |
| SCHEMBL5996194 | 0.63 | CYP2C8 (0.40) | RORC | |
| SCHEMBL7255108 | 0.63 | KEAP1 (0.46) | MMP9 | |
| SCHEMBL8176308 | 0.61 | POLB (0.36) | TP53MEN1KMT2AL3MBTL1 | |
| SCHEMBL7449311 | 0.60 | MEN1 (0.33) | MEN1KMT2AMMP2MMP9 | |
| Carbamic Acid SCHEMBL7116890 | 0.60 | KMT2A (0.69) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL17258939 | 0.60 | TP53 (0.50) | TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-7829564-B2 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2009-01-22 | — | — | US | disclosed |
| US-6534493-B1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE | 2003-03-18 | — | — | US | disclosed |
| US-6472407-B1 | α and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023664-A1 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | DNPEP, ASPH, PREP | TP53 1482/4885MMP8 635/4885MEN1 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.